Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Buys Scios: Will Natrecor Make Another Centocor?

Executive Summary

Johnson & Johnson will gain access to Scios' Phase II oral rheumatoid arthritis program through its proposed $2.4 bil. acquisition of the biotech company

You may also be interested in...



Seeking Turnaround, Myrexis Taps Two New Execs

Rather than pursue a sale, Myrexis will obtain revenue-generating drugs that it feels are underperforming in other hands. Until it chooses an asset to acquire, it will operate as a virtual company.

Natrecor Labeling Revised To Include Expanded Mortality Analysis

Johnson & Johnson/Scios' Natrecor (nesiritide) labeling has been revised to include an expanded analysis of the mortality rates seen in pivotal trials of the congestive heart failure agent

Natrecor Labeling Revised To Include Expanded Mortality Analysis

Johnson & Johnson/Scios' Natrecor (nesiritide) labeling has been revised to include an expanded analysis of the mortality rates seen in pivotal trials of the congestive heart failure agent

Related Content

UsernamePublicRestriction

Register

PS041280

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel